Organon & Co. (NYSE:OGN) Short Interest Down 15.9% in April

Organon & Co. (NYSE:OGN) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 18,609,663 shares, a drop of 15.9% from the March 31st total of 22,133,518 shares. Currently, 7.3% of the company’s stock are short sold. Based on an average daily volume of 9,901,209 shares, the short-interest ratio is presently 1.9 days.

Institutional Trading of Organon & Co.

A number of hedge funds and other institutional investors have recently made changes to their positions in OGN. Royal Bank of Canada increased its position in shares of Organon & Co. by 53.4% during the first quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock worth $5,374,000 after purchasing an additional 125,648 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Organon & Co. by 126.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after purchasing an additional 801,307 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Organon & Co. by 2.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock valued at $15,530,000 after acquiring an additional 26,640 shares during the period. Focus Partners Wealth increased its position in Organon & Co. by 33.2% in the 1st quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock valued at $832,000 after acquiring an additional 13,925 shares during the period. Finally, XTX Topco Ltd acquired a new position in Organon & Co. in the 2nd quarter valued at about $107,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and lifted their price target for the stock from $5.00 to $14.00 in a report on Tuesday. Barclays lifted their price target on Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a report on Tuesday, February 24th. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. BNP Paribas Exane reaffirmed a “neutral” rating and set a $14.00 price target (up from $12.00) on shares of Organon & Co. in a report on Wednesday. Finally, Wall Street Zen downgraded Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Four analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Organon & Co. presently has an average rating of “Reduce” and a consensus target price of $11.40.

Key Stories Impacting Organon & Co.

Here are the key news stories impacting Organon & Co. this week:

• Positive Sentiment: Board declared a quarterly cash dividend of $0.02 per share (record May 11, payable June 11), implying an annualized yield of ~0.6% — a modest shareholder return that supports income-focused holders.
• Neutral Sentiment: Company press release provides the quarter’s segment detail: total revenue $1.46B (down ~4% vs. Q1 2025). Women’s Health revenue fell ~16% (?19% ex-FX), Biosimilars grew ~23% (?21% ex-FX), Established Brands declined ~1% (?7% ex-FX). Useful for modeling near-term product-level trends. Organon Reports Results for the First Quarter Ended March 31, 2026
• Neutral Sentiment: Analyst write-ups (Zacks and snapshot pieces) dig into how headline numbers compare with estimates and prior year metrics — helpful for gauging margin drivers and consensus revisions. Organon (OGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
• Negative Sentiment: Reported Q1 EPS of $0.71 missed consensus ~$0.83 and declined from $1.02 a year ago; revenue $1.46B missed ~$1.49B. Net margin compressed (~3.0%) though ROE is elevated (122%) — the miss and weakening Women’s Health sales are the main near-term headwinds for forecasts and valuation. Organon (OGN) Q1 Earnings and Revenues Miss Estimates
• Negative Sentiment: High-profile negative commentary (e.g., Jim Cramer quoted as saying “Organon’s done” in a caller exchange) may amplify retail selling or sentiment volatility short-term. Jim Cramer Says “Organon’s Done” Upon a Caller’s Inquiry

Organon & Co. Stock Performance

Shares of OGN traded up $0.04 during midday trading on Friday, reaching $13.29. 9,978,163 shares of the stock were exchanged, compared to its average volume of 18,335,226. The business’s 50-day moving average price is $7.68 and its 200 day moving average price is $7.76. The company has a debt-to-equity ratio of 11.47, a current ratio of 1.82 and a quick ratio of 1.23. Organon & Co. has a twelve month low of $5.69 and a twelve month high of $13.39. The company has a market capitalization of $3.49 billion, a price-to-earnings ratio of 18.72, a PEG ratio of 1.23 and a beta of 1.57.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, May 7th. The company reported $0.71 EPS for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). Organon & Co. had a return on equity of 103.27% and a net margin of 3.99%.The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter last year, the firm posted $1.02 EPS. The firm’s revenue for the quarter was down 3.5% on a year-over-year basis. On average, sell-side analysts expect that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Monday, May 11th will be given a dividend of $0.02 per share. The ex-dividend date is Monday, May 11th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.’s payout ratio is 11.27%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.